Protests
Genentech’s Divarasib Demonstrated Best-in-Class Efficacy, Advancing the Standard of Care in Previously Treated KRAS G12C-mutated Lung Cancer
Divarasib monotherapy demonstrated superior efficacy over first-generation KRAS G12C inhibitors, lowering the risk of disease progression or death by 42% and the overall risk of death by 44%, in the Phase III Krascendo 1 study At the time of primary analysis, divarasib achieved a median overall survival of approximately 18 months, compared to 12 months […]
Read the full story at Financial PostOpen in the live monitor